Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future

Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yu-Yan, Jenner, Peter, Chen, Sheng-Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925102/
https://www.ncbi.nlm.nih.gov/pubmed/34957948
http://dx.doi.org/10.3233/JPD-212976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925102/
https://www.ncbi.nlm.nih.gov/pubmed/34957948
http://dx.doi.org/10.3233/JPD-212976

Ejemplares similares